Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have hematologic cancer at risk of relapse.

Key facts

Study ID

NCT00003962

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

1998-04-01

Expected to finish

2000-06-01

Last updated by the study team

2014-05-02

Who can join

Age: any, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins Oncology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.